Is it safe to use Lyrica (pregabalin) or gabapentin together with blood thinners (anticoagulants)?

Safety of Lyrica (Pregabalin) and Gabapentin with Blood Thinners

Both Lyrica (pregabalin) and gabapentin can be safely used with blood thinners (anticoagulants) as there are no direct pharmacokinetic drug interactions between these medications. 1

No Direct Drug Interactions

The FDA label for Lyrica explicitly states that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions because it:

• Is predominantly excreted unchanged in the urine (>98%)
• Undergoes negligible metabolism (<2%)
• Does not bind to plasma proteins
• Does not interact with CYP450 enzymes or P-glycoprotein 1

Gabapentin and pregabalin do not affect the pharmacokinetics or anticoagulant effects of direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, or dabigatran. 2 A 2025 study specifically demonstrated that neither gabapentin nor pregabalin altered the exposure or blood levels of any factor Xa inhibitors. 2

Important Cardiovascular Safety Concerns

While there are no direct interactions with anticoagulants, recent evidence reveals significant cardiovascular risks with gabapentinoids that warrant careful consideration, especially in patients already requiring anticoagulation:

Short-term Risks (3 months):

• Increased risk of deep venous thrombosis (DVT): HR 1.37 3
• Increased risk of pulmonary embolism: HR 1.27 3
• Increased risk of peripheral vascular disease 4

Long-term Risks (1-5 years):

• Myocardial infarction: HR 1.25-1.31 3, 4
• Stroke: HR 1.26-1.44 3, 4
• Heart failure: HR 1.14-1.20 4, 5
• DVT: HR 1.78 at 5 years 3
• Pulmonary embolism: HR 1.86 at 5 years 3
• Atrial fibrillation: RR 2.79-2.91 6

Pregabalin carries a higher risk of heart failure compared to gabapentin (AHR 1.48), particularly in patients with pre-existing cardiovascular disease (AHR 1.85). 5

Clinical Recommendations

When prescribing gabapentinoids to patients on anticoagulants:

1. Assess cardiovascular risk profile carefully - Patients already requiring anticoagulation often have underlying cardiovascular disease, placing them at higher risk for gabapentinoid-related cardiovascular complications. 4, 5

2. Monitor for thrombotic events - Be vigilant for signs of DVT, pulmonary embolism, and peripheral vascular disease, even with short-term use (≥3 months). 3, 4

3. Consider alternative pain management - Given the increased cardiovascular risks and lack of superior efficacy over placebo in some conditions, evaluate whether gabapentinoids are truly necessary. 7

4. Renal function monitoring - Both drugs require dose adjustment in renal impairment, and patients on anticoagulants may have comorbid renal disease. 1

5. Watch for additive CNS effects - While not a bleeding interaction, gabapentinoids cause dizziness (30%) and somnolence (23%), which may increase fall risk in anticoagulated patients. 1

Common Pitfalls to Avoid

• Do not assume gabapentinoids are "safe" simply because there's no pharmacokinetic interaction - The cardiovascular risks are independent of anticoagulant interactions. 3, 4

• Do not overlook fluid retention and peripheral edema (6% incidence with Lyrica) - This can exacerbate heart failure and may be particularly problematic in cardiovascular disease patients. 1

• Do not prescribe long-term without reassessing risk-benefit - Cardiovascular risks increase with duration of use. 3, 4